Germany


Franchise Global to Acquire German Pharmaceutical and Medical Cannabis Products Distributor, Strengthening its Position in the German Pharmaceutical and Medical Cannabis Market

May 16th, 2022 - Ryan Allway

The acquisition is expected to strengthen operations and drive synergies in Germany, a key region of the Company’s growth strategy May 16, 2022 08:05 ET | Source: Franchise Global Health Inc. VANCOUVER, British Columbia , May 16, 2022 (GLOBE NEWSWIRE) — Franchise Global Health Inc. (“Franchise Global” or the “Company“) (TSX‑V: FGH; FRA: WV4A) is pleased to announce that it has entered into […]

Franchise Global Health Inc. Announces Europe’s first Legal, Registered Cannabis Seedbank

April 26th, 2022 - Ryan Allway

  Seedbank has audited value of more than C$9 million and core to Company’s IP strategy TORONTO, ON / ACCESSWIRE / April 28, 2022 / Franchise Global Health Inc. (“Franchise Global” or the “Company”) (TSXV:FGH) is pleased to announce the Company’s wholly owned Danish subsidiary, Rangers Pharmaceutical A/S (“Rangers”), has successfully established Europe’s first legal and registered seedbank in […]

Why You Should Invest in Europe’s Cannabis Industry (and Its Upcoming Leader)

April 25th, 2022 - Ryan Allway

  The North American cannabis industry has struggled over the past couple of years, but fundamentals are improving and valuations are becoming attractive. As North America continues to grapple with excess supply issues, challenging margins and regulations, investors are starting to turn their attention toward European markets that are in the early innings of adoption […]

Pure Extracts Exports First Shipment of Cannabis Oil Extracts to German Pharma Company

March 16th, 2022 - Ryan Allway

VANCOUVER, British Columbia, March 16, 2022 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that it has successfully exported its first batch of cannabis oil extracts […]

PharmaCielo Signs Sales Agreement with Greenstein to Supply THC Final Products that will be Commercialized through NOWEDA, a Pharmaceutical Wholesaler to all Pharmacies Across Germany

February 14th, 2022 - Ryan Allway

The Company will start supplying the German market with three THC-dominant products, with commercial shipments expected to begin in late 2022. This is PharmaCielo’s first sales agreement related to THC products. Represents a significant milestone related to management’s re-focusing of PharmaCielo’s product strategy toward THC-dominant products.   TORONTO and RIONEGRO, Colombia, Feb. 14, 2022 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or […]

Agra Ventures’ Subsidiary Farmako Positioned to Benefit from Germany’s Impending Legalization of Recreational Cannabis

February 11th, 2022 - Ryan Allway

The Company Congratulates the New German Government for Making the Legalization of Recreational Cannabis and Development of a Regulatory Framework a Priority for the Country in the Near Term   VANCOUVER, British Columbia, Feb. 11, 2022 (GLOBE NEWSWIRE) — Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (OTC: AGFAF) (FRA: PU30), a growth-oriented and diversified company focused on the international cannabis industry, is pleased […]

Orchid Ventures Announces Partnership with Eurox Pharma GmbH on Submission to German Authorities for Medical Device Approval

January 11th, 2022 - Ryan Allway

VANCOUVER, BC / ACCESSWIRE / January 11, 2022 / Orchid Ventures, Inc. (the “Company” or “Orchid“) (CSE:ORCD) (OTC PINK:ORVRF), a multi-state cannabis innovation company, today announced it has entered into an exclusive agreement with Eurox Pharma GmbH (“EUROX“), Germany based pharmaceutical company. Under the terms of the agreement, Eurox, PurTec, and JWEI, the Company’s OEM supplier […]

How to Capitalize on Germany’s Move to Legalize Cannabis

November 30th, 2021 - Ryan Allway

Germany’s incoming governing parties recently announced a formal agreement to legalize adult-use cannabis when they take power. While personal possession has already been decriminalized, the new proposal seeks to establish a regulated market for adult-use cannabis. The move could create an industry like those in Canada and some U.S. states. While the legislation won’t be […]

Eve & Co Completes its Largest to Date Shipment of Cannabis to Germany

August 11th, 2021 - Ryan Allway

STRATHROY, Ontario, Aug. 11, 2021 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce that it has, through its wholly-owned subsidiary Natural MedCo Ltd. (“NMC”), successfully completed its largest shipment of cannabis to a customer in Germany with a retail value of $1.8M CAD. Eve […]

Aleafia Health Completes Breakthrough Medical Cannabis Export to Germany

June 3rd, 2021 - Ryan Allway

TORONTO, June 03, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a global leader in cannabis wellness products and services, is pleased to announce that dried flower grown at its Niagara greenhouse facility has been successfully exported to Germany. Gaining access to Europe’s most mature legal cannabis […]

KI findet die Nadel im Heuhaufen

April 15th, 2021 - Makenzie Branch

   Jedes Jahr werden Tausende von Molekülen als Medikamentenkandidaten für eine Vielzahl von Krankheiten hergestellt, synthetisiert und getestet. MagicMed Industries bringt diesen pharmazeutischen Entwicklungsansatz auf dem Gebiet der Psychedelika zum Einsatz, um neue therapeutische Alternativen für Patienten mit Problemen der Gehirn- und psychischen Gesundheit zu schaffen. Die Entdeckung der richtigen Moleküle ist jedoch ein gewaltiges […]

Die Psybrary ™: 12 Abenteuergeschichten, bei denen Sie selbst eine von Millionen Endungen wählen können

March 12th, 2021 - Ryan Allway

Die Psybrary™ von MagicMed ist eine bemerkenswerte und beeindruckende Leistung, die mehr als geschätzten 125 Millionen Derivaten bis zu deren Patenterteilung Patentschutz bieten könnte. Während 125 Millionen Derivate eine große Zahl ist, sollten dabei zwei Dinge klargestellt werden. Erstens bedeutet diese Zahl nicht, dass das Unternehmen eine kleine Armee von Wissenschaftlern weggesperrt hat, um 125 […]

MagicMed wendet die Idee des Modells einer Bibliothek für Medikamentenkandidaten auch auf Psychedelika an

January 20th, 2021 - Ryan Allway

Der Psychedelika-Markt wird oft mit Wörtern, wie “aufstrebend”, “aufkeimend” und ähnlichen beschrieben, und obwohl dies sicherlich weitgehend zutrifft, sollten Anleger keinen Moment denken, dass dies alles neu ist. Das Gegenteil ist der Fall. Es gibt eine Vielzahl klinischer und präklinischer Daten, die vor dem Inkrafttreten des Gesetzes über kontrollierte Substanzen im Jahr 1970 gesammelt wurden. […]

MagicMed zielt mit dem Programm für pharmazeutische Derivate auf einen massiven Markt ab

December 23rd, 2020 - Ryan Allway

Der Markt für Psychedelika ist aufgrund des unentdeckten therapeutischen Potenzials psychedelischer Moleküle schwer zu berechnen. Die wissenschaftliche Gemeinschaft hat gezeigt, dass Psychedelika mehrere Milliarden-Dollar-Märkte im Bereich Gehirn und psychische Gesundheit behandeln können. MagicMed Industries zielt darauf ab, Teile beider Märkte zu erobern, indem es ein einzigartiges, patentgeschütztes Portfolio an geistigem Eigentum entwickelt, das mehrere Medikamentenkandidaten, […]

Innovation zahlt sich aus bei Psychedelika

December 18th, 2020 - Ryan Allway

Es besteht ein erhebliches Interesse am psychedelischen Bereich und an den vielversprechenden psychedelischen Molekülen für die Behandlung von psychischen Erkrankungen. Geisteskrankheiten sind eine allgegenwärtige menschliche Erfahrung und eine bisher nur unzureichend behandelte medizinische Notwendigkeit. Psychedelika bieten eine Alternative zu unwirksamen Behandlungen, da sie über andere Wirkmechanismen funktionieren. Psychedelische Arzneimittel müssen jedoch verbessert werden, um aus […]

Wie groß ist die psychedelische Gelegenheit?

October 29th, 2020 - Ryan Allway

Der nordamerikanische Markt für psychedelische Medikamente wird vorraussichtlich bis 2027 6.85 Milliarden USD erreichen, nach Daten der Data Bride Market Research, das entspricht einer jährlichen Wachstumsrate von 16.3%. Nach der Genehmigung von Johnson & Johnsons (NYSE: jnj) SPRAVATO Nasenspray für behandlusngsresistente Depressionen und zwei Breakthrough Therapie Bezeichnungen, sind Unternehmen, die Kapital beschaffen, um die  Multi-Milliarden-Dollar […]

3 Psychedelische Business Modelle (und was am besten für Investoren ist)

October 23rd, 2020 - Ryan Allway

Die Psychedelikaindustrie hat das Interesse von Pharmaunternehmen geweckt, die nach sichereren und effektiveren Produkten suchen, um ungedeckte medizinische Bedürfnisse im Bereich der psychischen Gesundheit zu befriedigen. Während psychedelische Moleküle vielversprechend sind, verlangen die Pharmahersteller, dass die Moleküle durch wissenschaftliche Techniken verbessert werden, um bestimmte therapeutische Ziele zu erreichen und Toxizitäten zu reduzieren. Es gibt drei […]

Wie der Psybrary ™ die Entdeckung psychedelischer Medikamente revolutionieren könnte Teilen

October 8th, 2020 - Ryan Allway

Laut Data Bridge Market Research wird der Markt für Psychedelika in den nächsten acht Jahren voraussichtlich mit einer durchschnittlichen jährlichen Wachstumsrate von 16,3% wachsen und bis 2026 6,85 Mrd. USD erreichen. Mit der Perspektive, eine breite Palette von psychischen Störungen zu behandeln führen bereits mehrere Organisationen klinische Studien in diesem Bereich durch. Werfen wir einen […]

MagicMed Industries Closes Oversubscribed Private Placement for $1,642,880 with Mackie Research Capital Corporation

September 2nd, 2020 - Ryan Allway

CALGARY, AB, Sept. 2, 2020 /CNW/ – MagicMed Industries Inc. (“MagicMed” or the “Company“) is pleased to announce that it has completed, and oversubscribed, its previously announced brokered private placement (the “Offering“) for gross proceeds of $1,642,880.  Pursuant to the Offering, the Company issued 6,571,520 new common shares at a price of $0.25 per common share.  The Company now has 20,111,520 […]

MagicMed möchte Partnern bei der Entwicklung von Psychedelika in Pharmaqualität helfen

July 22nd, 2020 - Ryan Allway

Durch die zunehmende Verbreitung von psychischen Erkrankungen und die steigende Akzeptanz von Psychedelika zur Behandlung dieser Krankheiten, rechnet das Data Bridge Market Research Zentrum mit einer durchschnittlichen jährlichen Wachstumsrate in der Psychedelika-Industrie von 16,3% auf 6,85 Mrd. USD. Mit mehr als 15 börsennotierten Unternehmen haben Anleger eine immer mehr Optionen, in diesem Bereich. MagicMed Industries […]

Europe: The Cannabis Industry’s Next Emerging Market

September 19th, 2019 - Ryan Allway

The global cannabis industry is projected to reach $66.3 billion by 2025, according to Grand View Research, representing a 23.9 percent compound annual growth rate. While North America has become a market leader, European markets are quickly catching up with their own liberalized laws. The market for health and wellness products, such as cannabidiol (CBD) […]

XPhyto Therapeutics Ready to Be Cannabis’ Newest Public Entity

August 2nd, 2019 - Ryan Allway

Only days after announcing that its wholly owned subsidiary was awarded a German cannabis and cultivation and extraction licence, XPhyto Therapeutics is ready to enter the public domain. With a final prospectus filed with the British Columbia Securities Commission, XPhyto is ready to go public on the CSE under the ticker “XPHY”. The company will […]

XPhyto Therapeutics: Where Medical Cannabis Meets Modern Science

July 25th, 2019 - Ryan Allway

  It wasn’t long ago that recreational marijuana was legalized in Washington State and Colorado, while speculation about widespread medical marijuana was running rampant across America and then-Canadian Prime Minister candidate Justin Trudeau was making campaign promises for his country to become the second in the world with adult-use marijuana. At that time, so-called “pot […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading